Biodesix (NASDAQ:BDSX) shares surged in early Monday trading after the lung diagnostics firm reported preliminary 2025 revenue that eclipsed its own upwardly revised guidance.
The company’s focus on high-margin lung cancer testing and a strategic expansion into primary care drove a 41% revenue spike in the fourth quarter.
Karyopharm Therapeutics (NASDAQ:KPTI) is entering a pivotal year for its oncology pipeline, with the company forecasting a duo of high-stakes clinical trial readouts that could redefine its market position as its current cash runway nears its end.
Boston Scientific Corp. (NYSE:BSX) has entered into a definitive agreement to acquire Valencia Technologies Corp., a private medical technology firm, in a strategic move to dominate the high-growth market for overactive bladder treatments.
BioAge Labs (NASDAQ:BIOA) shares climbed Monday after the longevity-focused biotech reported that its experimental oral drug, BGE-102, sharply reduced systemic inflammation in a mid-stage study of obese patients.
Nuvation Bio (NYSE:NUVB) reported preliminary 2025 revenue that beat internal projections, driven by the rapid adoption of its flagship lung cancer treatment, IBTROZI®.
Planet Fitness (NYSE:PLNT) reported a surge in year-end membership and same-club sales for 2025, signaling that its low-cost "Judgment Free Zone" model is continuing to capture market share among younger, budget-conscious consumers.
Lipocine (NASDAQ:LPCN) experimental oral treatment for postpartum depression passed its final independent safety review, clearing the path for a critical data readout later this spring.
Hyperfine (NASDAQ:HYPR), the medical technology firm behind the first portable, AI-powered brain imaging system, reported a dramatic surge in fourth-quarter revenue, signaling a potential turning point for its bedside MRI technology.
Moderna (NASDAQ:MRNA) projected 2025 sales at the upper end of its forecast as a smaller-than-expected decline in U.S. vaccination rates and aggressive cost-cutting help the biotech giant navigate the post-pandemic landscape.
KORU Medical Systems (NASDAQ:KRMD) reported preliminary 2025 revenue that exceeded the high end of its guidance on Monday, as the medical technology firm prepares to pivot from its core immunology business into the high-growth oncology market.
Cellares and Cabaletta Bio (NASDAQ:CABA) announced a landmark regulatory achievement Monday, with the FDA clearing an Investigational New Drug (IND) Amendment to manufacture the autoimmune-focused CAR T therapy, rese-cel, using Cellares’ fully automated platforms.
GeneDx Holdings Corp. (NASDAQ:WGS) issued a bullish outlook for 2026 on Monday, forecasting revenue to exceed the half-billion-dollar milestone as the company’s pivot to high-margin exome and genome sequencing gains unprecedented traction.
